Tuesday, April 29, 2008 11:55:55 AM
HERCULES, Calif.- April 28, 2008 - Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of a product brochure on its BioPlexR suspension array system.
Entitled "Bio-Plex Suspension Array System", the 22-page product brochure covers features and benefits of the Bio-Plex system including workstation software, assay development tools, and the various Bio-Plex ProT assays. The brochure provides detailed lists of all of its available assays for the system in addition to ordering information.
The Bio-Plex suspension array system is a powerful array technology platform that offers reliable multiplex assays. The system is composed of all of the products necessary for a complete workflow, from sample preparation reagents and diluents to sophisticated data analysis software. The fully integrated system can enable protein and nucleic acid researchers to analyze up to 100 biomolecules in a single sample, with accurate reproducible assay results.
The assays are multiplexable bead-based assays based on xMAP technology and optimized for the Bio-Plex suspension array system. The assays and associated products include cytokines, chemokines, growth factors, diabetes, acute phase, angiogenesis, phosphoproteins, and isotyping.
Bio-Plex assays can also be run on the Luminex 100 or 200 systems.
Availability
The brochure is available either from a local Bio-Rad sales office or it can be requested by visiting the Bio-Rad web site at http://www.bio-rad.com/bio-plexassays.
About Bio-Rad
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
For more information contact:
Emily C. Dale
Bio-Rad Laboratories, Inc.
510-741-6571
Emily_Dale@bio-rad.com
Recent BIO News
- Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference • Business Wire • 05/01/2024 01:00:00 PM
- Bio-Rad Announces Life Science Group Management Changes • Business Wire • 04/26/2024 12:30:00 PM
- Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • Business Wire • 04/18/2024 01:00:00 PM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Bio-Rad’s Chief Operating Officer Andrew Last to Retire • Business Wire • 04/10/2024 08:15:00 PM
- Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer • Business Wire • 03/20/2024 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day • Business Wire • 02/22/2024 09:30:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results • Business Wire • 02/15/2024 09:15:00 PM
- Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 • Business Wire • 01/24/2024 10:00:00 PM
- Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference • Business Wire • 01/02/2024 09:15:00 PM
- Bio-Rad Reports Third-Quarter 2023 Financial Results • Business Wire • 10/26/2023 08:15:00 PM
- Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 • Business Wire • 10/05/2023 12:30:00 PM
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference • Business Wire • 08/28/2023 08:15:00 PM
- Bio-Rad Reports Second-Quarter 2023 Financial Results • Business Wire • 08/03/2023 08:15:00 PM
- Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement • Business Wire • 07/26/2023 08:15:00 PM
- Bio-Rad Announces New Share Repurchase Program • Business Wire • 07/20/2023 08:30:00 PM
- Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023 • Business Wire • 07/10/2023 08:30:00 PM
- Bio-Rad Publishes Corporate Sustainability Report for 2022 • Business Wire • 07/10/2023 01:00:00 PM
- Bio-Rad to Present Company Overview at Jefferies Healthcare Conference • Business Wire • 06/01/2023 12:00:00 PM
- Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/08/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM